Opus Genetics, Inc.
IRD
$1.96
-$0.03-1.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.25% | -28.19% | -42.30% | -85.35% | -63.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.25% | -28.19% | -42.30% | -85.35% | -63.67% |
| Cost of Revenue | 62.12% | 75.27% | 49.83% | 41.58% | 12.20% |
| Gross Profit | -546.47% | -1,144.98% | -2,157.61% | -139.66% | -108.14% |
| SG&A Expenses | 67.44% | 39.01% | 52.35% | 31.96% | 28.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.87% | 60.34% | 52.19% | 34.56% | 16.25% |
| Operating Income | -144.53% | -198.97% | -222.58% | -201.37% | -183.07% |
| Income Before Tax | -313.50% | -419.27% | -476.82% | -193.52% | -174.28% |
| Income Tax Expenses | -- | -- | -- | -100.61% | -96.19% |
| Earnings from Continuing Operations | -313.15% | -418.72% | -476.13% | -194.58% | -175.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -313.15% | -418.72% | -476.13% | -194.58% | -175.60% |
| EBIT | -144.53% | -198.97% | -222.58% | -201.37% | -183.07% |
| EBITDA | -144.44% | -198.98% | -222.70% | -201.33% | -183.01% |
| EPS Basic | -234.28% | -317.85% | -340.15% | -178.92% | -160.17% |
| Normalized Basic EPS | -63.63% | -124.33% | -141.61% | -177.79% | -158.76% |
| EPS Diluted | -229.00% | -310.27% | -331.92% | -182.45% | -164.60% |
| Normalized Diluted EPS | -60.30% | -119.16% | -135.88% | -181.44% | -163.54% |
| Average Basic Shares Outstanding | 62.22% | 29.25% | 23.76% | 18.22% | 13.92% |
| Average Diluted Shares Outstanding | 60.60% | 27.88% | 22.40% | 15.97% | 14.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |